AI Article Synopsis
- The FDA has approved a new live fecal microbiota product called Rebyota.
- Rebyota is designed to help prevent the recurrence of Clostridioides difficile infections in adults.
- It is specifically approved for use after antibiotic treatment for recurrent C. difficile episodes.
Article Abstract
The Food and Drug Administration has approved a live fecal microbiota product (Rebyota) to prevent recurrence of Clostridioides difficile in adults.The product is approved for use following antibiotic treatment for recurrent episodes of C. difficile.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000944904.20242.ae | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of risk factors of infection in patients with inflammatory bowel disease.
Prz Gastroenterol
September 2024
Department of Internal Medicine and Gastroenterology with Inflammatory Bowel Disease Unit, National Medical Institute of the Ministry of Interior and Administration, Warsaw, Poland.
Introduction: infection (CDI) is one of the most important challenges in contemporary gastroenterology. However, data from CDI studies are sometimes contradictory.
Aim: To analyse the risk factors for CDI in patients with inflammatory bowel disease (IBD).
Background: Rising nosocomial infections pose high risks, especially for immunocompromised leukemia patients, necessitating targeted research to enhance patient care and outcomes.The objective of this study was to investigate the impact of nosocomial infections (CDI) on patients hospitalized with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).
Methods: Our study was a retrospective analysis of adult patients hospitalized with a primary diagnosis of ALL or AML, using the Nationwide Inpatient Sample (NIS) database for 2020.
Pilot study of infection (CDI) in hospitals, Italy, September to December 2022.
Euro Surveill
January 2025
The members of this group are listed under Acknowledgements.
Background infection (CDI) is a severe infection that needs to be monitored. This infection predominantly occurs in hospitalised patients after antimicrobial treatment, with high mortality in elderly patients.AimWe aimed at estimating the incidence of CDI in Italian hospitals over 4 months in 2022.
View Article and Find Full Text PDFEvaluating Harms Associated with Prolonged Antibiotic Duration of Therapy in Community Dwelling Older Adults: A Cohort Study using Instrumental Variable Analysis.
Clin Infect Dis
December 2024
Public Health Ontario; Dalla Lana School of Public Health, University of Toronto; Unity Health Toronto.
Background: Shorter courses of antibiotic therapy are increasingly recommended to reduce antibiotic exposure. However quantifying the real-world impact of duration of therapy is hindered by bias common in observational studies. We aimed to evaluate the harms and benefits of longer versus shorter duration of therapy in older adults.
View Article and Find Full Text PDFCharacterization of heparin interactions with Clostridioides difficile toxins and its potential as anti-CDI therapeutics.
Carbohydr Polym
March 2025
Department of Molecular Medicine, Morsani College of Medicine, University of South Florida Tampa, FL 33620, USA. Electronic address:
Clostridioides difficile (C. difficile) infection (CDI) is a life-threatening healthcare-associated infection occurring worldwide. C.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!